Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Romiplostim N01 for Enhancement of Platelet Engraftment After Autologous Hematopoietic Stem Cell Transplantation
ChiCTR2500096999Phase 4Not yet recruiting
- Sponsor
- First Affiliated Hospital of Nanchang University
- Start
- Feb 2025
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of romiplostim in multiple myeloma (MM), lymphoma, leukemia and 1 more, sponsored by First Affiliated Hospital of Nanchang University. Primary endpoint: Time to platelet engraftment. Planned start Feb 2025; status: not yet recruiting.
02
Drugs
romiplostim
03
Conditions
multiple myeloma (MM)lymphomaleukemiaThrombocytopenia
Beyond the preview
Go deeper on ChiCTR2500096999.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500096999.